Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure?
| Autor: | Giovannella Palmieri, Davide Bosso, Michele Caraglia, Matteo Ferro, Mimma Rizzo, Simona Malgieri, Giuseppe Di Lorenzo, Francesco Perri, Carlo Buonerba, Piera Federico |
|---|---|
| Přispěvatelé: | Buonerba, C, Caraglia, Michele, Malgieri, S, Perri, F, Bosso, D, Federico, P, Ferro, M, Rizzo, M, Palmieri, G, Di Lorenzo, G. |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Pharmacology
Vitamin medicine.medical_specialty Kidney Calcitriol business.industry Clinical Biochemistry Urology Renal function Bone metastasis medicine.disease chemistry.chemical_compound Zoledronic acid Denosumab medicine.anatomical_structure Endocrinology chemistry Internal medicine Drug Discovery Vitamin D and neurology Medicine business medicine.drug |
| Popis: | Denosumab has been proven to be at least as effective with respect to zoledronic acid in preventing skeletal-related events in patients with bone metastases from solid tumors. Although denosumab can be considered to have a more favorable toxicity profile compared to zoledronic acid in terms of kidney toxicity and flu-like symptoms, hypocalcemia is twice as frequent with denosumab. Importantly, denosumab is not metabolized by the kidney and it may be employed even in patients with severe kidney failure. Like zoledronic acid, denosumab is administered with oral calcium and vitamin D. As conversion of vitamin D to its active form is progressively impaired with a creatinine clearance < 70 ml/min, we speculate that calcitriol may be a better option than vitamin D in denosumab-treated patients with impaired kidney function. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|